Exploring serotonergic psychedelics as a treatment for personality disorders

IF 4.6 2区 医学 Q1 NEUROSCIENCES
Brennan M. Carrithers , Daniel E. Roberts , Brandon M. Weiss , Jacob D. King , Robin L. Carhart-Harris , Alexandra R. Gordon , Broc A. Pagni , Miltiadis Moreau , Stephen Ross , Richard J. Zeifman
{"title":"Exploring serotonergic psychedelics as a treatment for personality disorders","authors":"Brennan M. Carrithers ,&nbsp;Daniel E. Roberts ,&nbsp;Brandon M. Weiss ,&nbsp;Jacob D. King ,&nbsp;Robin L. Carhart-Harris ,&nbsp;Alexandra R. Gordon ,&nbsp;Broc A. Pagni ,&nbsp;Miltiadis Moreau ,&nbsp;Stephen Ross ,&nbsp;Richard J. Zeifman","doi":"10.1016/j.neuropharm.2025.110413","DOIUrl":null,"url":null,"abstract":"<div><div>Both psychotherapeutic interventions and pharmacological agents have demonstrated limited efficacy in the treatment of personality disorders (PDs). Emerging evidence suggests that psychedelic therapy, already showing promise in treating various psychiatric conditions commonly comorbid with PDs, may exert therapeutic effects by promoting adaptive changes in personality. Thus, psychedelic therapy could hold potential for addressing core features of PDs through shared mechanisms of personality modulation. Although historical literature and observational studies suggest the potential clinical utility of psychedelics in treating PDs, rigorous research is lacking, and individuals with PDs are often excluded from modern psychedelic therapy trials. In the present review, we first discuss research on the effects of psychedelics in individuals with a PD through the conventional lens of the Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.; DSM-5-TR) categorical model. Next, using the dimensional DSM Alternative Model of Personality Disorders (DSM-AMPD) as a framework, we examine how psychedelics may affect self-functioning, interpersonal functioning, and pathological personality traits. We conclude by discussing the clinical relevance of psychedelic therapy as a treatment for personality pathology, including safety considerations, gaps and limitations, and recommendations for approaching psychedelic therapy within these more complex clinical populations.</div></div>","PeriodicalId":19139,"journal":{"name":"Neuropharmacology","volume":"272 ","pages":"Article 110413"},"PeriodicalIF":4.6000,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0028390825001194","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Both psychotherapeutic interventions and pharmacological agents have demonstrated limited efficacy in the treatment of personality disorders (PDs). Emerging evidence suggests that psychedelic therapy, already showing promise in treating various psychiatric conditions commonly comorbid with PDs, may exert therapeutic effects by promoting adaptive changes in personality. Thus, psychedelic therapy could hold potential for addressing core features of PDs through shared mechanisms of personality modulation. Although historical literature and observational studies suggest the potential clinical utility of psychedelics in treating PDs, rigorous research is lacking, and individuals with PDs are often excluded from modern psychedelic therapy trials. In the present review, we first discuss research on the effects of psychedelics in individuals with a PD through the conventional lens of the Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.; DSM-5-TR) categorical model. Next, using the dimensional DSM Alternative Model of Personality Disorders (DSM-AMPD) as a framework, we examine how psychedelics may affect self-functioning, interpersonal functioning, and pathological personality traits. We conclude by discussing the clinical relevance of psychedelic therapy as a treatment for personality pathology, including safety considerations, gaps and limitations, and recommendations for approaching psychedelic therapy within these more complex clinical populations.
探索5 -羟色胺类致幻剂治疗人格障碍。
心理治疗干预和药物治疗在人格障碍(pd)的治疗中都显示出有限的疗效。越来越多的证据表明,迷幻药疗法在治疗pd共病的各种精神疾病方面已经显示出前景,它可能通过促进人格的适应性改变来发挥治疗效果。因此,迷幻疗法可能通过共同的人格调节机制来解决pd的核心特征。尽管历史文献和观察性研究表明致幻剂在治疗pd方面具有潜在的临床应用价值,但缺乏严谨的研究,并且患有pd的个体经常被排除在现代致幻剂治疗试验之外。在本综述中,我们首先通过《精神疾病诊断与统计手册》(第5版,文本修订版;DSM-5-TR)分类模型。接下来,使用DSM人格障碍的维度替代模型(DSM- ampd)作为框架,我们研究了迷幻药如何影响自我功能,人际功能和病理人格特征。最后,我们讨论了致幻剂治疗作为人格病理学治疗的临床相关性,包括安全性考虑,差距和局限性,以及在这些更复杂的临床人群中进行致幻剂治疗的建议。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Neuropharmacology
Neuropharmacology 医学-神经科学
CiteScore
10.00
自引率
4.30%
发文量
288
审稿时长
45 days
期刊介绍: Neuropharmacology publishes high quality, original research and review articles within the discipline of neuroscience, especially articles with a neuropharmacological component. However, papers within any area of neuroscience will be considered. The journal does not usually accept clinical research, although preclinical neuropharmacological studies in humans may be considered. The journal only considers submissions in which the chemical structures and compositions of experimental agents are readily available in the literature or disclosed by the authors in the submitted manuscript. Only in exceptional circumstances will natural products be considered, and then only if the preparation is well defined by scientific means. Neuropharmacology publishes articles of any length (original research and reviews).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信